Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Condition:   Healthy Volunteers (Meningococcal Infection) Interventions:   Biological: Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine;   Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine;   Biological: Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine;   Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine;   Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine;   Biological: Haemophilus b Conjugate Vaccine;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Biological: Rotavirus Vaccine, Live, Oral, Pentavalent;   Biological: Hepatitis B Vaccine;   Biological: Measles, Mumps, and Rubella Virus Vaccine Live;   Biological: Varicella Virus  Vaccine Live Sponsor:   Sanofi Pasteur, a Sanofi Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials